MacroGenics announced additional details of the results from the Phase 3 Sophia study of margetuximab in patients with HER2-positive metastatic breast cancer who have previously been treated with anti-HER2-targeted therapies.
About 53 million people worldwide use opioids or their natural counterparts and nearly half of them develop substance-abuse disorders leading to about 118,000 overdose deaths every year, According to the World Health Organization. More…
Iovance Biotherapeutics is one of the early big winners from ASCO. The firm announced updates from ongoing clinical trials including new interim data from studies of patients with advanced cervical cancer and advanced melanoma.
Health care instrument maker Agilent is getting hammered Wednesday following a worse-than-expected earnings report for the company's second fiscal quarter. The company's outlook for the rest of the year made matters worse.
Solid Biosciences shares were crumbling on Tuesday after the firm announced its first-quarter results and an update to its midstage Duchenne muscular dystrophy trial.
The 55th annual meeting of the American Society of Clinical Oncology (ASCO) is just around the corner. Biotech and pharmaceutical companies will descend on Chicago for a five-day all-out conference (May 31 to June…
The April 30 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
The April 30 short interest data have been compared with the previous figures, and short interest in most of these selected marijuana stocks increased.
It's an impressive day when two IPOs are well received when drug-selling revenues are unlikely for quite some time, and even longer before profits can be considered.
Mylan is scheduled to release its first-quarter financial results before the markets open on Tuesday, and earnings are expected to be lower than a year ago.
It’s no simple task for a biotech giant to try to sell itself to investors as a value stock. That has been the case for some time when it comes to Gilead Sciences, Inc.…